<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<xbrli:xbrl xmlns:xbrli="http://www.xbrl.org/2003/instance"
            xmlns="http://www.w3.org/1999/xhtml"
            xmlns:arr="http://xbrl.dcca.dk/arr"
            xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12"
            xmlns:cmn="http://xbrl.dcca.dk/cmn"
            xmlns:sob="http://xbrl.dcca.dk/sob"
            xmlns:link="http://www.xbrl.org/2003/linkbase"
            xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
            xmlns:ix="http://www.xbrl.org/2013/inlineXBRL"
            xmlns:mrv="http://xbrl.dcca.dk/mrv"
            xmlns:fsa="http://xbrl.dcca.dk/fsa"
            xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
            xmlns:gsd="http://xbrl.dcca.dk/gsd"
            xmlns:xlink="http://www.w3.org/1999/xlink"
            xml:lang="en">
   <link:schemaRef xlink:href="http://archprod.service.eogs.dk/taxonomy/20241001/entryDanishGAAPBalanceSheetAccountFormIncomeStatementByNatureIncludingManagementsReviewStatisticsAndTax20241001.xsd"
                   xlink:type="simple"/>
   <xbrli:context id="ctx-1">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-2">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfExecutiveBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-3">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>1</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-4">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>2</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-5">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>3</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-6">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfMemberOfSupervisoryBoardDimension">
            <cmn:memberOfBoardIdentifier>4</cmn:memberOfBoardIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-7">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
            <cmn:auditorIdentifier>1</cmn:auditorIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-8">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:typedMember dimension="cmn:IdentificationOfAuditorDimension">
            <cmn:auditorIdentifier>2</cmn:auditorIdentifier>
         </xbrldi:typedMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-9">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
   </xbrli:context>
   <xbrli:context id="ctx-10">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-11">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-12">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:startDate>2024-06-27</xbrli:startDate>
         <xbrli:endDate>2025-03-31</xbrli:endDate>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RevaluationReserveMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-13">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:ContributedCapitalMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-14">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RevaluationReserveMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:context id="ctx-15">
      <xbrli:entity>
         <xbrli:identifier scheme="http://www.dcca.dk/cvr">44931478</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
         <xbrli:instant>2025-03-31</xbrli:instant>
      </xbrli:period>
      <xbrli:scenario>
         <xbrldi:explicitMember dimension="fsa:ClassesOfEquityDimension">fsa:RetainedEarningsMember</xbrldi:explicitMember>
      </xbrli:scenario>
   </xbrli:context>
   <xbrli:unit id="dkk">
      <xbrli:measure>iso4217:DKK</xbrli:measure>
   </xbrli:unit>
   <xbrli:unit id="pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
   </xbrli:unit>
   <gsd:DateOfGeneralMeeting contextRef="ctx-1" id="id-wrvauhllytt">2025-06-06</gsd:DateOfGeneralMeeting>
   <gsd:NameAndSurnameOfChairmanOfGeneralMeeting contextRef="ctx-1" id="id-lvxank3h9m9" xml:lang="en">Ole Wiborg</gsd:NameAndSurnameOfChairmanOfGeneralMeeting>
   <sob:IdentificationOfApprovedAnnualReport contextRef="ctx-1" id="id-klzzzcnog8e" xml:lang="en">The Board of Directors and the Executive Board have today considered and approved the annual report of Dispersome IP ApS for the financial year 27.06.2024 - 31.03.2025.</sob:IdentificationOfApprovedAnnualReport>
   <sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement contextRef="ctx-1" id="id-k3wvzqmbhqe" xml:lang="en">The annual report is presented in accordance with the Danish Financial Statements Act.</sob:ConfirmationThatAnnualReportIsPresentedInAccordanceWithRequirementsProvidedForByLegislationAnyStandardsAndRequirementsProvidedByArticlesOfAssociationOrByAgreement>
   <sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults contextRef="ctx-1" id="id-rbctjxhb6p" xml:lang="en">In our opinion, the financial statements give a true and fair view of the Entity’s financial position at 31.03.2025and of the results of its operations for the financial year 27.06.2024 - 31.03.2025.</sob:ConfirmationThatFinancialStatementGivesTrueAndFairViewOfAssetsLiabilitiesEquityFinancialPositionAndResults>
   <sob:ManagementsStatementAboutManagementsReview contextRef="ctx-1" id="id-3ks6hj7e7ol" xml:lang="en">We believe that the management commentary contains a fair review of the affairs and conditions referred to therein.</sob:ManagementsStatementAboutManagementsReview>
   <sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting contextRef="ctx-1" id="id-jydoyu16bo" xml:lang="en">We recommend the annual report for adoption at the Annual General Meeting.</sob:RecommendationForApprovalOfAnnualReportByGeneralMeeting>
   <sob:PlaceOfSignatureOfStatement contextRef="ctx-1" id="id-ve3w9zzm2o" xml:lang="en">Copenhagen</sob:PlaceOfSignatureOfStatement>
   <sob:DateOfApprovalOfAnnualReport contextRef="ctx-1" id="id-yi2ddmx9a6h">2025-05-15</sob:DateOfApprovalOfAnnualReport>
   <cmn:NameAndSurnameOfMemberOfExecutiveBoard contextRef="ctx-2" id="id-0v8t9yo2dlv8" xml:lang="en">Christoph Brücher</cmn:NameAndSurnameOfMemberOfExecutiveBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-3" id="id-2pfp5uk8e7a" xml:lang="en">Ole Sylvester-Hvid Wiborg</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:TitleOfMemberOfSupervisoryBoard contextRef="ctx-3" id="id-a3p656h9i68" xml:lang="en">chairman</cmn:TitleOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-4" id="id-zsqdcovtx6k" xml:lang="en">Márcio Milton Nunes Temtem</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-5" id="id-2cualarr5fn" xml:lang="en">Korbinian Arthur Maria Löbmann</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <cmn:NameAndSurnameOfMemberOfSupervisoryBoard contextRef="ctx-6" id="id-iwk9qmd8ecg" xml:lang="en">Christoph Brücher</cmn:NameAndSurnameOfMemberOfSupervisoryBoard>
   <arr:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements contextRef="ctx-1" id="id-ngfq74ar1m" xml:lang="en">To the shareholders of Dispersome IP ApS</arr:AddresseeOfAuditorsReportOnExtendedReviewOfFinancialStatements>
   <arr:OpinionOnFinancialStatementsExtendedReview contextRef="ctx-1" id="id-oz2kaenqu7" xml:lang="en">We have performed an extended review of the financial statements of Dispersome IP ApS for the
 ​financial year 27.06.2024 - 31.03.2025, which comprise the income statement, 
balance sheet, statement of
 changes in equity and notes, including a summary of significant 
accounting policies. The financial statements
 are prepared in accordance with the Danish Financial Statements Act.
​​​Based on our extended review, in our opinion, the financial statements give a true and fair view of the Entity’s
​​financial position at 31.03.2025 and of the results of its operations for the 
financial year 27.06.2024 - 31.03.2025in accordance with the Danish Financial 
Statements Act.</arr:OpinionOnFinancialStatementsExtendedReview>
   <arr:DescriptionOfQualificationsOfFinancialStatementsExtendedReview contextRef="ctx-1" id="id-d8xa0yjj28h" xml:lang="en">We conducted our extended review in accordance with the assurance engagement standard for small enterprises
​as issued by the Danish Business Authority and the standard on extended review of financial statements
​prepared in accordance with the Danish Financial Statements Act as issued by FSR - Danish Auditors.
 Our responsibilities under those standards and requirements are further described in the ”Auditor’s responsibilities
 for the extended review of the financial statements” section. We are independent of the Entity in accordance with the International Ethics Standards Board for Accountants’ International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the evidence we have obtained is
 sufficient and appropriate to provide a basis for our conclusion.</arr:DescriptionOfQualificationsOfFinancialStatementsExtendedReview>
   <arr:MaterialUncertaintyConcerningGoingConcernExtendedReview contextRef="ctx-1" id="id-puczjosfifm" xml:lang="en">Reference is made to note 1 in the financial statements which describes the significant uncertainties related to
​the company's ability to continue as a going concern. Without modifying our opinion, we draw attention to Management’s assessment that material uncertainty exists about the Company’s ability to continue as a going concern.
​
​We note that the Company’s ability to continue as a going concern depends on continued funding from its joint owners. Management assesses that such funding will be made available as needed.
​
​Consequently, the financial statements have been prepared on a going-concern basis. We refer to the description​in Note 1, which outlines the matter and the material uncertainty regarding going concern.
​
​We have found no basis for a different assessment; therefore, this matter has not modified our opinion.
</arr:MaterialUncertaintyConcerningGoingConcernExtendedReview>
   <arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview contextRef="ctx-1" id="id-maksh6jgfxh-1" xml:lang="en">Management is responsible for the preparation of financial statements that give a true and fair view in accordance
 with the Danish Financial Statements Act, and for such internal control as Management determines
​is necessary to enable the preparation of financial statements that are free from material misstatement,
​whether due to fraud or error.​​In preparing the financial statements, Management is responsible for assessing the Entity’s ability to continue
​as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless Management either intends to liquidate the Entity or to cease operations, or has
 no realistic alternative but to do so.</arr:StatementOfExecutiveAndSupervisoryBoardsResponsibilityForFinancialStatementsExtendedReview>
   <arr:StatementOfAuditorsResponsibilityExtendedReview contextRef="ctx-1" id="id-o4bxm6pmq4" xml:lang="en">Our responsibility is to express a conclusion on the financial statements. This requires that we plan and
​perform procedures to obtain limited assurance about our conclusion on the financial statements and that
​we also perform specifically required supplementary procedures for the purpose of obtaining additional assurance
 about our conclusion.​​An extended review consists of making inquiries, primarily of Management and, if appropriate, of other entity
​personnel, performing analytical and the specifically required supplementary procedures as well as evaluating
​the evidence obtained.​​The procedures performed in an extended review are less in scope than in an audit, and accordingly we do
​not express an audit opinion on the financial statements.</arr:StatementOfAuditorsResponsibilityExtendedReview>
   <arr:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview contextRef="ctx-1" id="id-yjdwu352wb-1" xml:lang="en">Management is responsible for the management commentary.
​​Our conclusion on the financial statements does not cover the management commentary, and we do not express
​any form of assurance conclusion thereon.
​​In connection with our extended review of the financial statements our responsibility is to read the management
​commentary and, in doing so, consider whether the management commentary is materially inconsistent
​with the financial statements or our knowledge obtained in the extended review or otherwise appears to be
​materially misstated.
​​Moreover, it is our responsibility to consider whether the management commentary provides the information
​required by relevant law and regulations.Based on the work we have performed, we conclude that the management commentary is in accordance with
​financial statements and has been prepared in accordance with the requirements in the relevant law and regulations. We did not identify any material misstatement of the management commentary.​​​​​​​​​​</arr:StatementOnManagementsReviewAuditorsReportOnExtendedReviewFinancialStatementsExtendedReview>
   <arr:SignatureOfAuditorsPlace contextRef="ctx-1" id="id-83hya547j0v" xml:lang="en">Copenhagen</arr:SignatureOfAuditorsPlace>
   <arr:SignatureOfAuditorsDate contextRef="ctx-1" id="id-oz17mqal4ol">2025-05-15</arr:SignatureOfAuditorsDate>
   <cmn:NameAndSurnameOfAuditor contextRef="ctx-7" id="id-wsqbykzqiug" xml:lang="en">Henrik Wolff Mikkelsen</cmn:NameAndSurnameOfAuditor>
   <cmn:DescriptionOfAuditor contextRef="ctx-7" id="id-vrsu910hs9" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
   <cmn:IdentificationNumberOfAuditor contextRef="ctx-7" id="id-ri98l87ewjl">mne33747</cmn:IdentificationNumberOfAuditor>
   <cmn:NameAndSurnameOfAuditor contextRef="ctx-8" id="id-wsuu54roeti" xml:lang="en">Leon Thomas Ravn Fagerlind</cmn:NameAndSurnameOfAuditor>
   <cmn:DescriptionOfAuditor contextRef="ctx-8" id="id-ankezeaqwtc" xml:lang="en">State Authorised Public Accountant</cmn:DescriptionOfAuditor>
   <cmn:IdentificationNumberOfAuditor contextRef="ctx-8" id="id-ev9mlwgmaz">mne49914</cmn:IdentificationNumberOfAuditor>
   <mrv:DescriptionOfPrimaryActivitiesOfEntity contextRef="ctx-1" id="id-c2cxm6pmdpl" xml:lang="en">Primary activitiesDispersome IP ApS holds the IP Rights to Dispersome® technology, which targets enhancement of the solubility and bioavailability of poorly soluble drugs using whey protein. The technology aims to improve therapeutic outcomes by increasing drug solubility and dissolution rates.</mrv:DescriptionOfPrimaryActivitiesOfEntity>
   <mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs contextRef="ctx-1" id="id-wsefe84ebf" xml:lang="en">Development in activities and financesThe financial result for the year amounted to a loss of TDKK 2,267 which is as expected by Management. ​​During the year, the company received a contribution in form of IP Rights from Zerion Pharma A/S.
​The Company is financed through contributions and loans from its joint venture partners. 
​​Dispersome IP ApS was established in 2024 by Zerion Pharma A/S. Subsequently 50 % of ownership where sold to Hovione Farmaciência S.A. Hence making it a joint venture between Zerion Pharma A/S and Hovione Farmaciência S.A., each holding 50% ownership, for the purpose of managing and commercializing the Dispersome® intellectual property portfolio.
</mrv:DescriptionOfDevelopmentInActivitiesAndFinancialAffairs>
   <mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod contextRef="ctx-1" id="id-velz8llqx2p" xml:lang="en">Events after the balance sheet dateNo significant events have occurred after the balance sheet date to this date.</mrv:DescriptionOfSignificantEventsOccurringAfterEndOfReportingPeriod>
   <fsa:GrossProfitLoss contextRef="ctx-1"
                        decimals="0"
                        id="id-b2j20mwx1fh"
                        unitRef="dkk">-1882197</fsa:GrossProfitLoss>
   <fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss contextRef="ctx-1"
                                                                                                                                 decimals="0"
                                                                                                                                 id="id-kzjgm0mxei"
                                                                                                                                 unitRef="dkk">1004606</fsa:DepreciationAmortisationExpenseAndImpairmentLossesOfPropertyPlantAndEquipmentAndIntangibleAssetsRecognisedInProfitOrLoss>
   <fsa:ProfitLossFromOrdinaryOperatingActivities contextRef="ctx-1"
                                                  decimals="0"
                                                  id="id-yntqvh4yju"
                                                  unitRef="dkk">-2886803</fsa:ProfitLossFromOrdinaryOperatingActivities>
   <fsa:OtherFinanceIncome contextRef="ctx-1"
                           decimals="0"
                           id="id-u5g98aveex"
                           unitRef="dkk">39</fsa:OtherFinanceIncome>
   <fsa:FinanceExpensesArisingFromGroupEnterprises contextRef="ctx-1"
                                                   decimals="0"
                                                   id="id-as32zgqfcyf"
                                                   unitRef="dkk">17660</fsa:FinanceExpensesArisingFromGroupEnterprises>
   <fsa:RestOfOtherFinanceExpenses contextRef="ctx-1"
                                   decimals="0"
                                   id="id-w17pesqc8qm"
                                   unitRef="dkk">3069</fsa:RestOfOtherFinanceExpenses>
   <fsa:ProfitLossFromOrdinaryActivitiesBeforeTax contextRef="ctx-1"
                                                  decimals="0"
                                                  id="id-rxpvoz8aegb"
                                                  unitRef="dkk">-2907493</fsa:ProfitLossFromOrdinaryActivitiesBeforeTax>
   <fsa:TaxExpense contextRef="ctx-1"
                   decimals="0"
                   id="id-39s1x8fykfk"
                   unitRef="dkk">-639648</fsa:TaxExpense>
   <fsa:ProfitLoss contextRef="ctx-1"
                   decimals="0"
                   id="id-mxhgkd9ukg"
                   unitRef="dkk">-2267845</fsa:ProfitLoss>
   <fsa:TransferredToFromRetainedEarnings contextRef="ctx-1"
                                          decimals="0"
                                          id="id-ileplzsdkf"
                                          unitRef="dkk">-2267845</fsa:TransferredToFromRetainedEarnings>
   <fsa:ProfitLoss contextRef="ctx-1"
                   decimals="0"
                   id="id-508yekgfq8l"
                   unitRef="dkk">-2267845</fsa:ProfitLoss>
   <fsa:AcquiredIntangibleAssets contextRef="ctx-9"
                                 decimals="0"
                                 id="id-4csex46mm1k"
                                 unitRef="dkk">23714598</fsa:AcquiredIntangibleAssets>
   <fsa:IntangibleAssets contextRef="ctx-9"
                         decimals="0"
                         id="id-fh8ztwhwo2p"
                         unitRef="dkk">23714598</fsa:IntangibleAssets>
   <fsa:NoncurrentAssets contextRef="ctx-9"
                         decimals="0"
                         id="id-ixo18rebhhj"
                         unitRef="dkk">23714598</fsa:NoncurrentAssets>
   <fsa:OtherShorttermReceivables contextRef="ctx-9"
                                  decimals="0"
                                  id="id-rjm7jyrb47"
                                  unitRef="dkk">102449</fsa:OtherShorttermReceivables>
   <fsa:ShorttermReceivables contextRef="ctx-9"
                             decimals="0"
                             id="id-aqeawvh0nno"
                             unitRef="dkk">102449</fsa:ShorttermReceivables>
   <fsa:CashAndCashEquivalents contextRef="ctx-9"
                               decimals="0"
                               id="id-834mn0bdjb9"
                               unitRef="dkk">1352004</fsa:CashAndCashEquivalents>
   <fsa:CurrentAssets contextRef="ctx-9"
                      decimals="0"
                      id="id-we7wrg1xsh9"
                      unitRef="dkk">1454453</fsa:CurrentAssets>
   <fsa:Assets contextRef="ctx-9"
               decimals="0"
               id="id-nwalhgqp4gr"
               unitRef="dkk">25169051</fsa:Assets>
   <fsa:ContributedCapital contextRef="ctx-9"
                           decimals="0"
                           id="id-azhttcsdgf5"
                           unitRef="dkk">40000</fsa:ContributedCapital>
   <fsa:RevaluationReserve contextRef="ctx-9"
                           decimals="0"
                           id="id-1n3m065chkr"
                           unitRef="dkk">18497386</fsa:RevaluationReserve>
   <fsa:RetainedEarnings contextRef="ctx-9"
                         decimals="0"
                         id="id-btnzv5zuw3m"
                         unitRef="dkk">-1484252</fsa:RetainedEarnings>
   <fsa:Equity contextRef="ctx-9"
               decimals="0"
               id="id-m1g00xl7hp"
               unitRef="dkk">17053134</fsa:Equity>
   <fsa:ProvisionsForDeferredTax contextRef="ctx-9"
                                 decimals="0"
                                 id="id-9lfaz554xfi"
                                 unitRef="dkk">4798577</fsa:ProvisionsForDeferredTax>
   <fsa:Provisions contextRef="ctx-9"
                   decimals="0"
                   id="id-odd0kpu9m8b"
                   unitRef="dkk">4798577</fsa:Provisions>
   <fsa:ShorttermTradePayables contextRef="ctx-9"
                               decimals="0"
                               id="id-wjfnarhwlmo"
                               unitRef="dkk">455642</fsa:ShorttermTradePayables>
   <fsa:ShorttermPayablesToGroupEnterprises contextRef="ctx-9"
                                            decimals="0"
                                            id="id-fag8qvreqyl"
                                            unitRef="dkk">2861698</fsa:ShorttermPayablesToGroupEnterprises>
   <fsa:ShorttermLiabilitiesOtherThanProvisions contextRef="ctx-9"
                                                decimals="0"
                                                id="id-0sk5q9kkry2c"
                                                unitRef="dkk">3317340</fsa:ShorttermLiabilitiesOtherThanProvisions>
   <fsa:LiabilitiesOtherThanProvisions contextRef="ctx-9"
                                       decimals="0"
                                       id="id-8il29si8t2t"
                                       unitRef="dkk">3317340</fsa:LiabilitiesOtherThanProvisions>
   <fsa:LiabilitiesAndEquity contextRef="ctx-9"
                             decimals="0"
                             id="id-v2a62csz85"
                             unitRef="dkk">25169051</fsa:LiabilitiesAndEquity>
   <fsa:CashPaymentsConcerningFormationOfEntity contextRef="ctx-10"
                                                decimals="0"
                                                id="id-8q3e599op1f"
                                                unitRef="dkk">40000</fsa:CashPaymentsConcerningFormationOfEntity>
   <fsa:CashPaymentsConcerningFormationOfEntity contextRef="ctx-11"
                                                decimals="0"
                                                id="id-zxyk9a7cyg"
                                                unitRef="dkk">0</fsa:CashPaymentsConcerningFormationOfEntity>
   <fsa:CashPaymentsConcerningFormationOfEntity contextRef="ctx-1"
                                                decimals="0"
                                                id="id-ehcyqtyfd9g"
                                                unitRef="dkk">40000</fsa:CashPaymentsConcerningFormationOfEntity>
   <fsa:Revaluations contextRef="ctx-12"
                     decimals="0"
                     id="id-1wtiif7305n"
                     unitRef="dkk">19280979</fsa:Revaluations>
   <fsa:Revaluations contextRef="ctx-1"
                     decimals="0"
                     id="id-5yrdxwhpb9r"
                     unitRef="dkk">19280979</fsa:Revaluations>
   <fsa:DissolutionOfReserves contextRef="ctx-12"
                              decimals="0"
                              id="id-qynxycnshtc"
                              unitRef="dkk">-783593</fsa:DissolutionOfReserves>
   <fsa:DissolutionOfReserves contextRef="ctx-11"
                              decimals="0"
                              id="id-vtrl49gshy"
                              unitRef="dkk">783593</fsa:DissolutionOfReserves>
   <fsa:DissolutionOfReserves contextRef="ctx-1"
                              decimals="0"
                              id="id-79weyn0haoj"
                              unitRef="dkk">0</fsa:DissolutionOfReserves>
   <fsa:ProfitLoss contextRef="ctx-11"
                   decimals="0"
                   id="id-gackjkq0ycf"
                   unitRef="dkk">-2267845</fsa:ProfitLoss>
   <fsa:ProfitLoss contextRef="ctx-1"
                   decimals="0"
                   id="id-p7ldn7hltcq"
                   unitRef="dkk">-2267845</fsa:ProfitLoss>
   <fsa:Equity contextRef="ctx-13"
               decimals="0"
               id="id-297wiolktro"
               unitRef="dkk">40000</fsa:Equity>
   <fsa:Equity contextRef="ctx-14"
               decimals="0"
               id="id-ik6jtmbrh2p"
               unitRef="dkk">18497386</fsa:Equity>
   <fsa:Equity contextRef="ctx-15"
               decimals="0"
               id="id-e1312jqoabv"
               unitRef="dkk">-1484252</fsa:Equity>
   <fsa:Equity contextRef="ctx-9"
               decimals="0"
               id="id-hjoz86q85bj"
               unitRef="dkk">17053134</fsa:Equity>
   <fsa:StatementOfChangesInEquity contextRef="ctx-1" id="id-aobq2eqm04" xml:lang="en">During the financial year, the company received a contribution of intellectual property rights by the joint venture partner, Zerion Pharma A/S, prior to Hovione Farmaciência S.A. entering into co-ownership. As part of the initial recognition hereof, the Company carried out a valuation of the intangible assets, now known as the Dispersome®​intellectual property rights. The determined cost price reflects the assessed fair value of the IP portfolio and has been recognized less deferred tax, directly on equity under a separate revaluation reserve.
 </fsa:StatementOfChangesInEquity>
   <fsa:DisclosureOfUncertaintiesRelatingToGoingConcern contextRef="ctx-1" id="id-ynwm2c5szw" xml:lang="en">1 Material uncertainty related to going concernThe operations of the company are funded by its joint owners. It is Management's expectation, that sufficient funds will continue to be made available, in order for the company to continue as a going concern and preserve the IP rights held within the company. Consequently, Management has prepared the annual report under a going concern assumption.</fsa:DisclosureOfUncertaintiesRelatingToGoingConcern>
   <fsa:DisclosureOfTaxExpenses contextRef="ctx-1" id="id-1d0utjm8wi4" xml:lang="en">2 Tax on profit/loss for the year2024/25​DKKChange in deferred tax(639,648)(639,648)</fsa:DisclosureOfTaxExpenses>
   <fsa:DisclosureOfIntangibleAssets contextRef="ctx-1" id="id-vud4o6x8l8" xml:lang="en">3 Intangible assetsAcquired intangible assets​DKKAdditions24,719,204Cost end of year24,719,204Amortisation for the year(1,004,606)Amortisation and impairment losses end of year(1,004,606)Carrying amount end of year23,714,598</fsa:DisclosureOfIntangibleAssets>
   <fsa:DisclosureOfProvisionsForDeferredTax contextRef="ctx-1" id="id-avzute2jp3w" xml:lang="en">4 Deferred taxDeferred tax relates to intangible assets and tax loss carry forward. Deferred tax liabilities related to intangible assets are recognised following the depreciaiton of the related assets (refer to note 3).</fsa:DisclosureOfProvisionsForDeferredTax>
   <fsa:DisclosureOfEmployeeBenefitsExpense contextRef="ctx-1" id="id-qy1qb5v7akn" xml:lang="en">5 EmployeesThe Entity has no employees other than the Executive Board. The Executive Officer has not received any 
​​​remuneration.  2024/25Average number of full-time employees0</fsa:DisclosureOfEmployeeBenefitsExpense>
   <fsa:AverageNumberOfEmployees contextRef="ctx-1"
                                 decimals="0"
                                 id="id-4qx8zfdde1r"
                                 unitRef="pure">0</fsa:AverageNumberOfEmployees>
   <fsa:InformationOnReportingClassOfEntity contextRef="ctx-1" id="id-kn0a1zch4wg" xml:lang="en">This annual report has been presented in accordance with the provisions of the Danish Financial Statements
​Act governing reporting class B enterprises with addition of a few provisions for reporting class C.</fsa:InformationOnReportingClassOfEntity>
   <fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies contextRef="ctx-1" id="id-yvnj4c5yevk" xml:lang="en">Recognition and measurementAssets are recognised in the balance sheet when it is probable as a result of a prior event that future economic
​benefits will flow to the Entity, and the value of the asset can be measured reliably.
​​Liabilities are recognised in the balance sheet when the Entity has a legal or constructive obligation as a
​result of a prior event, and it is probable that future economic benefits will flow out of the Entity, and the
​value of the liability can be measured reliably.
​​On initial recognition, assets and liabilities are measured at cost. Measurement subsequent to initial
​recognition is effected as described below for each financial statement item.
​​Anticipated risks and losses that arise before the time of presentation of the annual report and that confirm
​or invalidate affairs and conditions existing at the balance sheet date are considered at recognition and
​measurement.
​​Income is recognised in the income statement when earned, whereas costs are recognised by the amounts
​attributable to this financial year.</fsa:DescriptionOfGeneralMattersRelatedToRecognitionMeasurementAndChangesInAccountingPolicies>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss contextRef="ctx-1" id="id-gddolhvuc" xml:lang="en">Gross profit or lossGross profit or loss comprises revenue, other operating income and consumables and external expenses.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfGrossProfitLoss>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales contextRef="ctx-1" id="id-nnkwih73pcs" xml:lang="en">Cost of salesCost of sales comprises goods consumed in the financial year measured at cost.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCostOfSales>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses contextRef="ctx-1" id="id-v0opes945" xml:lang="en">Other external expensesOther external expenses include expenses relating to the Entity’s ordinary activities, including expenses for
​premises, marketing costs and administrative costs.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfExternalExpenses>
   <fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation contextRef="ctx-1" id="id-laqv84jbuyk" xml:lang="en">Depreciation, amortisation and impairment lossesDepreciation, amortisation and impairment losses relating to intangible
 assets comprise depreciation, amortisation and impairment losses for the financial year.</fsa:DescriptionOfMethodsOfImpairmentLossesAndDepreciation>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncome contextRef="ctx-1" id="id-fakszz3v8du" xml:lang="en">Other financial incomeOther financial income  comprise interest income including interest income on transactions in foreign
​currencies etc.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceIncome>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceExpenses contextRef="ctx-1" id="id-fn2305pz9ko-1" xml:lang="en">Financial expenses from group enterprisesFinancial expenses from group enterprises comprise interest expenses etc. from payables to group
 enterprises.Other financial expensesOther financial expenses comprise interest expenses, including interest expenses on transactions in foreign
​currencies etc.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfFinanceExpenses>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses contextRef="ctx-1" id="id-uhwlpt5nt7" xml:lang="en">Tax on profit/loss for the yearTax for the year, which consists of current tax for the year and changes in deferred tax, is recognised in the
​income statement by the portion attributable to the profit for the year and recognised directly in equity by
 the portion attributable to entries directly in equity.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxExpenses>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets contextRef="ctx-1" id="id-vv0534nbvse" xml:lang="en">Intellectual property rights etc.Intellectual property rights etc. comprise acquired intellectual property rights and prepayments for intangible assets.Intellectual property rights acquired are measured at cost less accumulated amortisation. Intellectual property rights are amortized over the period, where the company has exclusive rights to the IP, corresponding to 17 years. ​
​Intellectual property rights etc. are written down to the lower of recoverable amount and carrying amount.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfIntangibleAssets>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables contextRef="ctx-1" id="id-7m3wpn87ndu" xml:lang="en">ReceivablesReceivables are measured at amortised cost, usually equalling nominal value less writedowns for bad and
​doubtful debts.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfReceivables>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents contextRef="ctx-1" id="id-8hw80byb4ux" xml:lang="en">CashCash comprises bank deposits.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfCashAndCashEquivalents>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax contextRef="ctx-1" id="id-kyevulsk58c" xml:lang="en">Deferred taxDeferred tax is recognised on all temporary differences between the carrying amount and the tax-based
 value of assets and liabilities, for which the tax-based value is calculated based on the planned use of each asset. ​​Deferred tax assets, including the tax base of tax loss carryforwards, are recognised in the balance sheet at
​their estimated realisable value, either as a set-off against deferred tax liabilities or as net tax assets.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfTaxPayablesAndDeferredTax>
   <fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions contextRef="ctx-1" id="id-34y28viw7ca" xml:lang="en">Other financial liabilitiesOther financial liabilities are measured at amortised cost, which usually corresponds to nominal value.</fsa:DescriptionOfMethodsOfRecognitionAndMeasurementBasisOfLiabilitiesOtherThanProvisions>
   <cmn:TypeOfDisclosureRelatingToGoingConcern contextRef="ctx-1" id="id-m8ivnxtdsv">Væsentlig usikkerhed vedr. fortsat drift</cmn:TypeOfDisclosureRelatingToGoingConcern>
   <arr:TypeOfBasisForModifiedOpinionOnFinancialStatementsExtendedReview contextRef="ctx-1" id="id-e79xbuch1qb">Grundlag for konklusion</arr:TypeOfBasisForModifiedOpinionOnFinancialStatementsExtendedReview>
   <arr:TypeOfModifiedOpinionOnAuditedFinancialStatementsExtendedReview contextRef="ctx-1" id="id-e4mflht3awj">Konklusion</arr:TypeOfModifiedOpinionOnAuditedFinancialStatementsExtendedReview>
   <fsa:SelectedElementsFromReportingClassC contextRef="ctx-1" id="id-ua8w8ari3mq">true</fsa:SelectedElementsFromReportingClassC>
   <cmn:IdentificationNumberCvrOfAuditFirm contextRef="ctx-7" id="id-mrskzvg5ogr">33963556</cmn:IdentificationNumberCvrOfAuditFirm>
   <gsd:AddressOfAuditorDistrictName contextRef="ctx-7" id="id-76rwhnwnilf" xml:lang="en">København S</gsd:AddressOfAuditorDistrictName>
   <gsd:AddressOfAuditorPostCodeIdentifier contextRef="ctx-7" id="id-m717d2inlk" xml:lang="en">2300</gsd:AddressOfAuditorPostCodeIdentifier>
   <gsd:AddressOfAuditorStreetBuildingIdentifier contextRef="ctx-7" id="id-apxijue0yfe" xml:lang="en">6</gsd:AddressOfAuditorStreetBuildingIdentifier>
   <gsd:AddressOfAuditorStreetName contextRef="ctx-7" id="id-vsbxyo4cyj" xml:lang="en">Weidekampsgade</gsd:AddressOfAuditorStreetName>
   <cmn:NameOfAuditFirm contextRef="ctx-7" id="id-1kg9ohmn2u" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</cmn:NameOfAuditFirm>
   <gsd:RegisteredOfficeOfReportingEntity contextRef="ctx-1" id="id-9qs1je9oeb" xml:lang="en">Copenhagen</gsd:RegisteredOfficeOfReportingEntity>
   <gsd:AddressOfReportingEntityDistrictName contextRef="ctx-1" id="id-9x3owj7mqcl" xml:lang="en">Copenhagen</gsd:AddressOfReportingEntityDistrictName>
   <gsd:AddressOfReportingEntityPostCodeIdentifier contextRef="ctx-1" id="id-s0zvd85gkf" xml:lang="en">2100</gsd:AddressOfReportingEntityPostCodeIdentifier>
   <fsa:ClassOfReportingEntity contextRef="ctx-1" id="id-pl56ga6l37f">Regnskabsklasse B</fsa:ClassOfReportingEntity>
   <cmn:TypeOfAuditorAssistance contextRef="ctx-1" id="id-qfiqxed6nfo">Erklæring om udvidet gennemgang</cmn:TypeOfAuditorAssistance>
   <gsd:ReportingPeriodEndDate contextRef="ctx-1" id="id-l9dq28h8b2">2025-03-31</gsd:ReportingPeriodEndDate>
   <gsd:ReportingPeriodStartDate contextRef="ctx-1" id="id-jng64jg7i8b">2024-06-27</gsd:ReportingPeriodStartDate>
   <gsd:AddressOfReportingEntityStreetBuildingIdentifier contextRef="ctx-1" id="id-en6lxkh8e0h" xml:lang="en">3</gsd:AddressOfReportingEntityStreetBuildingIdentifier>
   <gsd:AddressOfReportingEntityStreetName contextRef="ctx-1" id="id-u0e1a6lubwp" xml:lang="en">Fruebjergvej</gsd:AddressOfReportingEntityStreetName>
   <gsd:NameOfReportingEntity contextRef="ctx-1" id="id-cgrpzzk6uut" xml:lang="en">Dispersome IP ApS</gsd:NameOfReportingEntity>
   <gsd:IdentificationNumberCvrOfReportingEntity contextRef="ctx-1" id="id-olpzmmj85w">44931478</gsd:IdentificationNumberCvrOfReportingEntity>
   <gsd:IdentificationNumberCvrOfSubmittingEnterprise contextRef="ctx-1" id="id-uo6dhz3pfm">33963556</gsd:IdentificationNumberCvrOfSubmittingEnterprise>
   <gsd:AddressOfSubmittingEnterprisePostcodeAndTown contextRef="ctx-1" id="id-w940os7bkok" xml:lang="en">2300  København S</gsd:AddressOfSubmittingEnterprisePostcodeAndTown>
   <gsd:AddressOfSubmittingEnterpriseStreetAndNumber contextRef="ctx-1" id="id-jyq5i1h3tdb" xml:lang="en">Weidekampsgade 6</gsd:AddressOfSubmittingEnterpriseStreetAndNumber>
   <gsd:NameOfSubmittingEnterprise contextRef="ctx-1" id="id-6yzx29fmlnu" xml:lang="en">Deloitte Statsautoriseret Revisionspartnerselskab</gsd:NameOfSubmittingEnterprise>
   <gsd:InformationOnTypeOfSubmittedReport contextRef="ctx-1" id="id-xle3836kvi">Årsrapport</gsd:InformationOnTypeOfSubmittedReport>
</xbrli:xbrl>
